Valore202020212022202320242025TTMSpese di vendita, generali e amministrative737.67 M759.38 M854.01 M937.29 M1.01 B1.15 B1.15 BRicerca e sviluppo628.12 M628.79 M649.61 M746.77 M747.18 M921.93 M921.93 MReddito operativo-36.77 M-82.34 M149.56 M158.1 M484.21 M409.48 M409.48 MProventi non operativi, Totale8.6 M12.29 M6.63 M30.64 M66.28 M68.8 M70.44 MOneri finanziari, al netto degli interessi capitalizzati29.31 M15.34 M15.97 M17.34 M12.67 M10.9 M10.9 MProventi non operativi, esclusi gli oneri finanziari-20.71 M-3.04 M-9.34 M13.3 M53.62 M57.91 M59.55 MEntrate/uscite straordinarie———————Utile al lordo delle imposte-42.32 M-75.35 M149.58 M188.56 M541.76 M482.48 M482.48 MQuota di utile-6 000——————Imposte-901.42 M-11.27 M8.02 M20.92 M114.9 M133.58 M133.58 MInteressi di minoranza———————Altri proventi/oneri al netto delle imposte997 K2.63 M2.04 M365 K-20.14 M4.41 M4.41 MUtile netto al lordo delle attività cessate859.1 M-64.08 M141.56 M167.65 M426.86 M348.9 M348.9 MAttività cessate———————Utile netto859.1 M-64.08 M141.56 M167.65 M426.86 M348.9 M348.9 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari867.41 M-64.08 M141.56 M167.65 M434.19 M356.24 M356.24 MUtile base per azione (EPS base)4.75-0.350.760.892.251.821.82Utile diluito per azione (EPS diluito)4.53-0.350.750.872.211.81.8Numero medio di azioni ordinarie in circolazione180.8 M182.85 M185.27 M187.83 M190.03 M191.79 M766.69 MAzioni diluite in circolazione191.68 M182.85 M188.96 M191.59 M196.71 M197.39 M782.99 MEBITDA68.41 M25.7 M251.53 M262.48 M580.64 M489.04 M489.04 MEBIT-36.77 M-82.34 M149.56 M158.1 M484.21 M409.48 M409.48 MCosto del fatturato524.27 M470.51 M483.67 M514.85 M580.24 M717.44 M717.44 MAltri costi del venduto75.61 M00——119.21 M—Ammortamento e svalutazione (liquidità)105.17 M108.04 M101.97 M104.39 M96.43 M79.56 M79.56 M
BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.